Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 2b study, 834 adults with BMI ≥25 kg/m2 and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%–10.5% [53–91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)—all administered subcutaneously. Coprimary end points were changes in HbA1c and body weight at week 14. The originally randomized interventions were continued to week 54. Liver damage biomarkers and liver fibrosis algorithms were assessed. RESULTS: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). Improvements in lipid profile, AST and ALT levels, propeptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score were observed with cotadutide 300 μg versus placebo, but not with liraglutide. Weight loss with cotadutide 200 μg was similar to that with liraglutide 1.8 mg and greater with cotadutide 300 μg versus liraglutide 1.8 mg. The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. CONCLUSIONS: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cotadutide, but not liraglutide improved hepatic parameters and metabolic dysfunction-associated steatohepatitis (MASH) with similar weight loss with 200 μg cotadutide compared to 1.8 mg liraglutide and greater with 300 μg cotadutide versus 1.8 mg liraglutide [47].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cotadutide did induce a dose-dependent 4–8 times greater reduction in triglycerides over liraglutide.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through a phase 2b trial, cotadutide 300 μg was shown to significantly improve liver injury enzymes, propeptide of type III collagen level, FIB-4, and NAFLD fibrosis score compared to placebo (but not compared to liraglutide) and reduce body weight more than treatment with liraglutide 1.8 mg.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [173]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from combining existing drugs, the development of dual GLP-1/glucagon receptor or GLP-1/GIP agonists or even triagonists237 with first promising results in NASH237–239 may show up another promising approach in drug development.”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [239]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“The pathology of NAFLD can progress further to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and end-stage cirrhosis (7).”
BackgroundByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“Because the majority of deaths linked with NAFLD are attributable to cardiovascular disease, and given the close association between type 2 diabetes and NAFLD, therapeutic agents that improve both liver health and cardiometabolic risk are clinically valuable (36,37).”
BackgroundFox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · cited 1×
“In previous studies of participants with obesity and NASH, weight loss achieved through lifestyle modifications decreased intrahepatic fat and ALT levels while improving hepatic fibrosis (32,33).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Lipid accumulation in non-adipose tissue and lipotoxicity
van Herpen, N. A., & Schrauwen-Hinderling, V. B. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.049 · Cited by 500
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih, M., & Jornayvaz, F. R. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.018 · Cited by 330
Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients
Ong, J. P., Elariny, H., Collantes, R., Younoszai, A., Chandhoke, V., Reines, H. D., Goodman, Z., & Younossi, Z. M. (2005) · Obesity Surgery · doi:10.1381/0960892053576820 · Cited by 322
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298 · cited 2×
“In a previous phase 2a study, cotadutide reduced subcutaneous and visceral adipose tissue (28).”
BackgroundSelf-citationTargher, G., & Byrne, C. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3093 · Cited by 297
Daniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273 · cited 1×
“direct marker of fibrogenesis and its use as a biomarker in those with type 2 diabetes can aid the identification of patients with moderately advanced and advanced fibrosis (34,35).”
BackgroundBoland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0209-6 · Cited by 270 · cited 2×
“Preclinical studies in diet-induced NASH mouse models showed significant reductions in NAFLD activity score and fibrosis with cotadutide treatment (26).”
BackgroundSelf-citationDai, W., Ye, L., Liu, A., Wen, S. W., Deng, J., Wu, X., & Lai, Z. (2017) · Medicine · doi:10.1097/md.0000000000008179 · Cited by 268
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218 · cited 2×
“Glucagon plays a role in the regulation of hepatic lipid metabolism by reducing hepatic lipid accumulation and secretion (38), as well as increasing LDL receptor expression (39).”
BackgroundNewsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186 · cited 1×
“Two years of treatment with semaglutide significantly reduced ALT and hs-CRP levels in patients with obesity and/or type 2 diabetes, although significance was lost after adjustment for changes in body weight (24).”
BackgroundGlucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
Perry, R. J., Zhang, D., Guerra, M. T., Brill, A. L., Goedeke, L., Nasiri, A. R., Rabin-Court, A., Wang, Y., Peng, L., Dufour, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2074-6 · Cited by 186
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Xiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164 · cited 1×
“GLP-1 regulates intestinal lipoprotein metabolism (41), while glucagon regulates hepatic lipoprotein metabolism (42).”
BackgroundPotts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundEffect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
Hannah, W. N., & Harrison, S. A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.008 · Cited by 163 · cited 1×
“In previous studies of participants with obesity and NASH, weight loss achieved through lifestyle modifications decreased intrahepatic fat and ALT levels while improving hepatic fibrosis (32,33).”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T. (2019) · Liver International · doi:10.1111/liv.14065 · Cited by 136
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Siddiqui, M. S., Van Natta, M. L., Connelly, M. A., Vuppalanchi, R., Neuschwander-Tetri, B. A., Tonascia, J., Guy, C., Loomba, R., Dasarathy, S., Wattacheril, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.006 · Cited by 135 · cited 1×
“In contrast, farnesoid X receptor agonists currently being tested in clinical trials for NAFLD are associated with increased levels of LDL cholesterol and total cholesterol and do not significantly impact body weight (45,46).”
BackgroundParker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123 · cited 2×
“The efficacy of cotadutide in providing glycemic control in participants with overweight or obesity and type 2 diabetes has been demonstrated in earlier studies (28,29).”
BackgroundSelf-citationInsulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
Gastaldelli, A. (2017) · Clinical Science · doi:10.1042/cs20170987 · Cited by 105
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 88 · cited 1×
“Because the majority of deaths linked with NAFLD are attributable to cardiovascular disease, and given the close association between type 2 diabetes and NAFLD, therapeutic agents that improve both liver health and cardiometabolic risk are clinically valuable (36,37).”
BackgroundRudling, M., & Angelin, B. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116522 · Cited by 76 · cited 2×
“Glucagon plays a role in the regulation of hepatic lipid metabolism by reducing hepatic lipid accumulation and secretion (38), as well as increasing LDL receptor expression (39).”
BackgroundEmerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundXiao, C., Pavlic, M., Szeto, L., Patterson, B. W., & Lewis, G. F. (2011) · Diabetes · doi:10.2337/db10-0763 · Cited by 60 · cited 1×
“GLP-1 regulates intestinal lipoprotein metabolism (41), while glucagon regulates hepatic lipoprotein metabolism (42).”
BackgroundXiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60 · cited 1×
“Metaanalyses demonstrate modest reductions in levels of fasting triglycerides and LDL cholesterol by GLP-1 receptor monoagonists (40).”
BackgroundKiapidou, S., Liava, C., Kalogirou, M., Akriviadis, E. A., & Sinakos, E. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.07.013 · Cited by 60
Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care · doi:10.2337/dc18-2578 · Cited by 52 · cited 1×
“direct marker of fibrogenesis and its use as a biomarker in those with type 2 diabetes can aid the identification of patients with moderately advanced and advanced fibrosis (34,35).”
BackgroundChen, L., Huang, J., Chen, Q., Lin, G.-F., Zeng, H., Lin, X.-F., Lin, X., Lin, L., & Lin, Q.-C. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000503 · Cited by 37
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33 · cited 1×
“Treatment with GLP-1 receptor monoagonists may also improve liver biomarkers (19).”
BackgroundJAIN, M., Tsai, L.-F., Robertson, D. C., Hirshberg, B., Hockings, P. D., JOHANSSON, L., & Ambery, P. (2018) · Diabetes · doi:10.2337/db18-78-or · Cited by 8
Self-citationRobertson, D. C., Parker, V., Ambery, P., Petrone, M., Wang, T., Heise, T., PLUM-MOERSCHEL, L., Jermutus, L., Hirshberg, B., & Meier, J. J. (2019) · Diabetes · doi:10.2337/db19-988-p · Cited by 5 · cited 1×
“The increased incidence of gastrointestinal adverse events may be attributed to a dose-dependent delay in gastric emptying time that was previously observed with cotadutide treatment (48).”
BackgroundSelf-citation
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“147 Triple agonist: Triple agonists go even further.”
BackgroundObesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Metadata
- Authors
- Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P.
- Affiliations
- AstraZeneca (United States) (US)
- Pennington Biomedical Research Center (US)
- AstraZeneca (Sweden) (SE)
- 5Division of Endocrinology, University Hospital Leipzig, Leipzig, Germany
- AstraZeneca (United Kingdom) (GB)
- 4Clinical Metabolism, Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Corresponding author
- Nahra, Rajaa
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-01
- Volume
- 44
- Issue
- 6
- Pages
- 1433-1442
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8247525
- OpenAlex
- W3160773731
- Semantic Scholar
- 0019fb9a1c6044e014f9a7ae0dd18ea9907668eb
- Cited by
- 323
- References
- 47
- Citations by year
- 2026: 36 · 2025: 65 · 2024: 76 · 2023: 83 · 2022: 48 · 2021: 14
- FWCI
- 41.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, glucagon receptor agonist, type 2 diabetes, obesity, overweight, glycemic control, HbA1c, weight loss, non-alcoholic fatty liver disease, liver fibrosis, liver injury biomarkers, liraglutide, lipid profile, adverse events, nausea and vomiting, dose comparison
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Obesity, Peptides, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.